Welcome to our dedicated page for Henry Schein news (Ticker: HSIC), a resource for investors and traders seeking the latest updates and insights on Henry Schein stock.
Overview
Henry Schein (HSIC) is a global powerhouse in the provision of health care products and services, servicing office-based dental, medical, and animal health practices. As a company with expansive reach in the health care distribution and medical supply sectors, Henry Schein leverages a centralized, automated distribution network to offer an extensive inventory that includes thousands of branded items alongside its own private-label products. With a focus on operational efficiency and quality care, Henry Schein remains a trusted partner for practitioners, dental laboratories, government, and institutional health care clinics worldwide.
Comprehensive Product and Service Portfolio
At its core, Henry Schein delivers more than just products; it provides a suite of integrated solutions designed to support and streamline clinical operations. The company’s portfolio spans a wide array of product categories including dental supplies, medical instruments, and animal health products. In addition, Henry Schein supports its customers with value-added services, practice management solutions, and innovative technologies that assist in optimizing operational success and enhancing clinical outcomes.
Technology Integration and Centralized Distribution
Central to Henry Schein's strategy is its robust, technology-driven approach which employs a centralized distribution network. This system not only ensures rapid and reliable delivery of essential medical supplies but also supports the high-volume inventory management necessary to meet the dynamic demands of global health care providers. By integrating advanced technology, the company facilitates streamlined order fulfillment, efficient supply chain management, and improved access to cutting-edge practice solutions.
Market Position and Competitive Landscape
Henry Schein holds a significant market position as one of the foremost providers in its industry. Its extensive global network, underscored by affiliations with major financial indexes and a comprehensive supplier ecosystem, positions it uniquely among its competitors. The company's scale, combined with its operational expertise, allows it to address complex logistical challenges and cater to diverse customer needs across various care settings. This makes Henry Schein a pivotal player in the competitive landscape of health care services and products.
Strategic Acquisitions and Innovation
The company’s portfolio has been further enhanced through strategic acquisitions. An example is its integration of specialized providers, such as the recent acquisition of a company with expertise in Continuous Glucose Monitors (CGM), which complements its broad product offering. Such moves reflect Henry Schein's commitment to innovation and comprehensive care solutions, strengthening its ability to serve diverse practice areas with tailored, technologically advanced products.
Operational Excellence and Value Proposition
Henry Schein’s primary value proposition lies in its dual commitment to quality and efficiency. The company excels in offering a seamless blend of extensive product inventory and integrated service solutions, ensuring that healthcare professionals can focus on delivering superior patient care. The reliance on an efficient distribution network, coupled with ongoing investment in technology, underscores the company’s role as a critical enabler for operational excellence within the health care sector.
Expertise and Industry Knowledge
With decades of experience, Henry Schein has cultivated deep expertise in the intricacies of health care supply chains. Its ability to manage a vast network and deliver specialized products across multiple practice areas is a testament to its operational sophistication. The company’s approach is rooted in a profound understanding of the challenges faced by healthcare providers, and its service model is crafted to address these challenges head on with credible, reliable, and expertly managed solutions.
In Summary
Henry Schein remains a formidable force in the health care product and service sector by continuously evolving to meet the needs of a diverse client base. Its strategic integration of technology, commitment to quality, and expansive product portfolio not only support clinical practices but also enhance overall customer experience. For investors and market analysts, Henry Schein stands out as a company with a solid operational foundation, leveraging a synergy of comprehensive solutions, strategic acquisitions, and a technology-first approach to maintain its influential market presence.
Henry Schein Medical (Nasdaq: HSIC) celebrated National Girls and Women in Sports Day 2025 by launching a video featuring four prominent WNBA athletic trainers. The video highlights Theresa Acosta (New York Liberty), Dr. Christina Kennedy (Washington Mystics), Natalie Trotter (Women's Professional Basketball Athletic Trainers Association), and Brittanie Vaughn (Seattle Storm).
The interviews explore their memorable career moments, the increasing presence of women in sports, and career advice. This marks the third year of Henry Schein Medical's Athletics and Schools business producing videos celebrating women athletic trainers, having featured 14 women ATs from three professional sports leagues to date.
The initiative aims to recognize athletic trainers' important role in athlete care and highlight the growing representation of women in sports medicine. In 2024, the company featured athletic trainers from five NBA teams.
Henry Schein (HSIC) announced a strategic investment from KKR, which will become the company's largest non-index fund shareholder with a 12% position through a $250 million investment. KKR can increase its stake to 14.9% through open market purchases.
The company reported preliminary Q4 2024 results with revenue of $3.2 billion and full-year 2024 revenue of $12.7 billion. Q4 GAAP EPS was $0.74, while non-GAAP EPS reached $1.19. Full-year 2024 GAAP EPS was $3.05, with non-GAAP EPS at $4.74.
For 2025, Henry Schein projects low to mid-single digit growth in both revenues and non-GAAP EPS. The company also announced a $500 million increase to its share repurchase program, with $250 million to be executed through accelerated share repurchases.
Henry Schein (NASDAQ: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, has announced its upcoming fourth quarter and full-year 2024 financial results release and conference call.
The company will release its financial results before market opening on Tuesday, February 25, 2025. A live webcast earnings conference call will follow at 8:00 a.m. Eastern time. The call will feature presentations from Stanley M. Bergman, Chairman of the Board and CEO, and Ronald N. South, Senior Vice President and CFO.
Investors can access the webcast through the company's investor relations website at https://investor.henryschein.com/webcasts. A replay of the presentation will be made available on the website afterward.
Henry Schein (HSIC) has completed the acquisition of substantially all assets of Acentus, a national medical supplier specializing in Continuous Glucose Monitors (CGMs). The deal, initially announced on November 20, 2024, brings Acentus founders Brett Carroll, Todd Cianfrocca, Greg Duvall, and Julio Valdivia into Henry Schein's team, incorporating their healthcare industry and product expertise.
The transaction was facilitated by Provident Healthcare Partners, with their deal team led by Managing Director Kevin Palamara. Robinson & Cole provided legal counsel to Acentus during the acquisition process. Acentus has developed a distinctive CGM platform that has shown significant growth since its establishment.
Henry Schein (Nasdaq: HSIC) has completed the acquisition of Acentus, a Tampa-based national medical supplier specializing in Continuous Glucose Monitors (CGMs) with annual revenue of approximately $35 million. The transaction is expected to be neutral to 2025 non-GAAP earnings per share and accretive thereafter.
This acquisition follows Henry Schein's previous acquisitions of Prism Medical Products (2021), Shield Healthcare, and Mini Pharmacy (2023), strengthening its position in the homecare medical supplies market. With the addition of Acentus, Henry Schein's homecare medical products platform will now have an annual revenue base exceeding $350 million.
The four Acentus founders will join Henry Schein, bringing their expertise in the product category and healthcare industry. The acquisition aims to enhance Henry Schein's ability to serve customers through direct CGM product delivery to patients' homes.
Henry Schein (Nasdaq: HSIC) has announced the opening of the Henry Schein Cares Foundation 2025 Relief Fund to support Los Angeles area fires relief efforts. The initiative includes a total commitment of up to $300,000, comprising:
- $25,000 each from the Company and Foundation
- Up to $50,000 in matching Team Schein Member contributions
- Up to $150,000 in essential healthcare supplies
The company has established a Customer Emergency Support Hotline (800-999-9729) for affected dental and medical professionals. The initiative aims to provide critical healthcare supplies and resources to communities impacted by the wildfires, working with trusted relief and recovery charitable partners.
Henry Schein (NASDAQ: HSIC) has activated its Customer Emergency Support Hotline at 800-999-9729 to assist dental and medical professionals affected by the ongoing California fires. The hotline provides 24/7 support, with live assistance from Team Schein Members available from 8 a.m. to 8 p.m. Eastern Time.
The company offers resources to help practitioners manage operational, logistical, and financial challenges resulting from the natural disaster. These include an Emergency Preparedness Guide to minimize disaster impact and an Emergency Recovery Guide to assist in practice rebuilding efforts.
Henry Schein (HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, has announced its participation in J.P. Morgan's Healthcare Investor Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 3:00 p.m. PST / 6:00 p.m. EST at The Westin St. Francis Hotel in San Francisco. Investors and interested parties can access the live webcast through www.henryschein.com/IRwebcasts, with replay options available on the company's website after the presentation.
Henry Schein (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, has announced its participation in two major investor conferences this December. The company will present at Piper Sandler's Healthcare Conference in New York on December 4, 2024, at 11:00 a.m. Eastern time, and at the Evercore ISI HealthCONx Conference in Coral Gables, Florida, on December 5, 2024, at 9:10 a.m. Eastern time. Both presentations will be available via live webcast on the company's website, with replays accessible afterward.
Henry Schein (NASDAQ: HSIC) has signed an agreement to acquire Acentus, a national medical supplier specializing in Continuous Glucose Monitors (CGMs) with annual revenue of $35 million. This acquisition follows Henry Schein's previous acquisitions of Prism Medical Products, Shield Healthcare, and Mini Pharmacy, expanding their homecare medical products platform to an annual revenue base of approximately $350 million. The transaction is expected to be neutral to 2024 non-GAAP earnings per share, accretive thereafter, and close in Q1 2025. Acentus's founders will join Henry Schein post-acquisition.
FAQ
What is the current stock price of Henry Schein (HSIC)?
What is the market cap of Henry Schein (HSIC)?
What is the primary business of Henry Schein?
How does Henry Schein support its customers?
What distinguishes Henry Schein in the competitive healthcare market?
How does Henry Schein generate its revenue?
What role does technology play in the company’s operations?
How are strategic acquisitions integrated into Henry Schein's business model?
Who are the main customers of Henry Schein?
How does Henry Schein ensure quality and operational efficiency?
